Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.95
Bid: 2.90
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.10 (3.448%)
Open: 2.95
High: 2.95
Low: 2.95
Prev. Close: 2.95
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

Fri, 15th Nov 2013 12:37

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Friday.

-------

FTSE 100 - Losers

Vedanta Resources is down 6.2%. The India-focused miner reported a plunge in pretax profit for the first half of the year, falling to USD261.1 million from USD1.07 billion in the previous year. Revenue declined 17% to USD6.16 billion from last year's USD7.45 billion. During the period, average prices received by Vedanta fell 9% for copper, 7% for aluminium and 3% for zinc, while average Brent oil prices were down 2%.

Centrica, down 2.1%, continues to slide after saying Thursday that it expects to report adjusted earnings per share at similar levels to last year. The figure had been up 2% at the half-year stage, so the outlook represents a deterioration in the second half. Additionally, it confirmed that it will take about GBP240 million in provisions for deciding not to proceed with an offshore gas storage project in Baird and to put the Caythorpe onshore project on hold indefinitely.

International Consolidated Airlines is down 1.6% despite raising its 2015 operating profit target. In a statement ahead of a capital markets day, the airline group said it is now targeting a EUR1.8 billion operating profit in 2015, up from its previous forecast for EUR1.6 billion. It raised its target for British Airways to GBP1.3 billion, from GBP1.1 billion, citing improved margins. Deutsche Bank analyst Anand Date says the upgrade of the company's guidance left unanswered questions. While overall profit was increased by only EUR200 million, BA profit was upgraded by GBP200 million, equivalent to EUR239 million, possibly implying a downgrade in estimates for Iberia, Data says.

-------

FTSE 250 - Winners

Genus, up 3.7%, is the index's leading riser. The animal genetics company's revenues and volumes have risen in recent months as its customers saw pork and beef prices rise and feed costs fall. The company said volumes of both products and services were up 5% between July 1 and November 14, with revenues up by the same amount at constant currencies. Additionally, Genus acquired Génétiporc's business in North America and Mexico in October, and said it was pleased with the initial reaction of customers and with the progress of integration.

African Barrick Gold climbs 2.5% after it said it had reached a deal with the Tanzanian State Mining Corporation, or Stamico, to sell its Tulawaka Gold Mine and certain exploration licenses surrounding Tulawaka for cash and future smelter royalties. In a statement, the gold miner said it would get USD4.5 million and be granted a 2% net smelter royalty on future production in excess of 500,000 ounces, capped at USD500,000. African Barrick had planned to close the mine. Under the deal, Stamico will take ownership and management of a rehabilitation fund that was established as part of the closure plan. It will also assume all the closure and rehabilitation liabilities and indemnify African Barrick against the liabilities. African Barrick will pay Stamico the USD17.6 million balance of the rehabilitation fund, minus the mine sale price.

Capital & Counties Properties, up 1.9%, has said that its Covent Garden estate continues to perform strongly with 14 new store openings since June. The company said it had secured new lettings and renewals at its Covent Garden site, representing annualised rental income of GBP2.7 million, with occupancy levels of 99% at September 30. The property investor also said detailed planning applications will be submitted for Earls Court Village after it received formal outline planning consent for its regeneration scheme. The Earls Court masterplan covers an area of 77 acres and provides for 10.1 million square feet of new residential-led, mixed-use space.

-------

FTSE 250 - Losers

Ultra Electronics Holdings is the biggest faller on the FTSE 250, down 6.1%. The defence, security, transport and energy group warned that it has been hit by the US government shutdown and a general slowdown in government spending in that market. It said the US shutdown delayed expected orders, approvals and payments, while many of the contracts it has won are still being funded incrementally. It also warned that it is continuing to experience delays on a contract in Oman, which means that it will now not be able to install its products until next year rather than in the fourth quarter.

Rotork is down 2.2%. The company reported that third quarter revenue was up 13% on last year, reflecting a strong performance across the business. In an interim management statement for the period July 1 to November 14, the company said it had benefited from currency movements which had been favourable throughout the year. However, the company has been on a strong run coming into the statement, with share price rising to 2,830.00 pence from 2,693.00 in mid-October, says Scott Cagehin, analyst at Numis. Despite this, the investment bank is confident about the company's growth profits, maintaining an Add recommendation, with a price target of 3,200.00p.

-------

AIM - Winners

Serica Energy climbs 9.4% after 67.4 million new shares started trading on AIM as part of the company's recent GBP14.3 million capital raising through a placing and open offer.

-------

AIM - Losers

Antrim Energy falls 40% despite reporting its first ever quarterly profit. The company with assets in the North Sea and offshore Ireland reported a net profit of USD930,000 for the second quarter of 2013, compared with a loss of USD6.4 million a year earlier. However, as a young company, Antrim gave its going concern disclaimer, saying there are a number of material uncertainties that raise significant doubts as to the company’s ability to continue as a going concern. Those include the performance of the producing wells, oil prices, ability to finish the planned development program for Causeway within budget, ability to secure additional financing, relinquishment of commitments on certain licences and settlement of contingencies.

ValiRx is down 18%. The pharmaceutical company said that it has raised GBP1 million in a placing of 307.7 million shares with institutional and other investors. The cancer drug developer said that it will use the funds to further advance its development programmes. Following the placing, ValiRx has 2.02 billion shares issued.

Cyan Holdings slides 10%. The software company said an Indian metering order worth over USD1 million that was won in 2012 and then delayed into 2013 has suffered a further delay and will now be delivered in 2014. Cyan had won the contract from a "major" metering customer in India, but there have since been delays by the Tamil Nadu energy company TNEB in tendering for the broader contract.

-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2013 07:53

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

Read more
24 Oct 2013 15:48

ValiRx Anti-Cancer Treatment Advances To Phase 2 Of Clinical Trial

Read more
3 Oct 2013 11:39

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

Read more
3 Oct 2013 08:08

ValiRx Cancer Treatment Files Escalation Study

Read more
5 Sep 2013 11:44

ValiRX reports encouraging progress despite losses

ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline. It reiterated that it expected results from the first stage of clinical trials for its

Read more
5 Sep 2013 09:20

ValiRx Losses Widen But Says Compounds Progressing In Trials

Read more
25 Apr 2013 10:02

ValiRx granted patent in Australia for VAL201 targeting cancer

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia. The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormon

Read more
2 Apr 2013 08:41

ValiRx to present at key Cancer Conference

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year. The conference, which was attended by approximately 17,000 delegates last year, is seen as a key eve

Read more
21 Feb 2013 13:17

ValiRx appoints COO to help build portfolio

Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy. Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identi

Read more
22 Nov 2012 15:56

Small cap round-up: InterQuest, ValiRx, Aeorema Comms

InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m p

Read more
11 Oct 2012 09:50

Contract wins round-up: LO-Q, Motive TV, Plexus ...

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's

Read more
29 May 2012 08:37

Small cap round-up: ValiRx, Transense, Sweett

Shares in ValiRx, the life sciences firm, leapt almost 40% on Tuesday after it said independent trials had confirmed the effectiveness of its prostate cancer drug VAL201. The firm said the "significant and substantively important findings" showed its drug reduced the spread of secondary tumours by u

Read more
15 May 2012 13:12

Small caps round-up: Cello, DDD, Kewill...

Marketing firm Cello Group has reported good trading during the first three months of the year, reflecting 'the strong pipeline of work secured at the end of 2011 and a solid flow of bookings'. The research and consulting division was a strong performer, while the group's focus on the pharmaceutic

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
2 Apr 2012 13:36

Small caps round-up: Rock Solid, ValiRx, InternetQ, Quindell

Rock Solid Images, an oil equipment, services and distribution firm, has received an offer from Thalassa Holdings to acquire up to 25.89 per cent of the company for 0.48p per share in cash. Rock Solid is concerned that Thalassa has provided no evidence that they will bring any "added economic or ind

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.